Intraperitoneal Paclitaxel Is Useful as Adjuvant Chemotherapy for Advanced Gastric Cancer with Serosal Exposure
Background: Intraperitoneal administration of paclitaxel (PTX) can elicit a marked clinical response in peritoneal metastases of gastric cancer. Methods: In this study, we retrospectively analyzed the clinical outcome of 17 patients who underwent R0 resection with D2 dissection for advanced gastric...
Main Authors: | Joji Kitayama, Hironori Ishigami, Hironori Yamaguchi, Shigenobu Emoto, Toshiaki Watanabe |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2014-01-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | http://www.karger.com/Article/FullText/358379 |
Similar Items
-
Pathological complete response after intraperitoneal paclitaxel and systemic combined chemotherapy in a patient with peritoneal metastases from gastric cancer: a case report
by: Yoshiyuki Meguro, et al.
Published: (2020-03-01) -
Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials
by: Sun Jingxu, et al.
Published: (2012-11-01) -
Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit
by: Tomohisa Yamamoto, et al.
Published: (2022-03-01) -
Phase II clinical trial of sequential treatment with systemic chemotherapy and intraperitoneal paclitaxel for gastric and gastroesophageal junction peritoneal carcinomatosis - STOPGAP trial
by: Maheswari Senthil, et al.
Published: (2023-03-01) -
Intraperitoneal Chemotherapy as Adjuvant or Perioperative Chemotherapy for Patients with Type 4 Scirrhous Gastric Cancer: PHOENIX-GC2 Trial
by: Hironori Ishigami, et al.
Published: (2021-11-01)